Merck (MRK) is near an agreement to acquire Cidara Therapeutics (CDTX), a drugmaker working on a long-acting flu antibody treatment, after besting rival pharma companies in a bidding war that went down to the wire, the Financial Times’ Oliver Barnes and James Fontanella-Khan report, citing people familiar with the matter. A transaction valuing the company at a premium tot its $3.3B market cap could be announced as soon as Friday, the authors note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Merck call volume above normal and directionally bullish
- Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls
- Scotiabank starts 10 large cap drugmakers with ‘out-of-consensus’ positive view
- Merck initiated with an Outperform at Scotiabank
- Midday Fly By: AMD sees acceleration, IBM unveils quantum processor